CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
insulin glarginedrug
Likely dose
insulin glargine 6 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00469833
NCT00469833N/ACompleted
CompareCT.gov

Pathogenesis of the Impaired Incretin Effect in Type 2 Diabetes

US Department of Veterans Affairs·interventional·Posted May 7, 2007·Updated Jan 15, 2015

In Brief

A clinical study evaluating insulin glargine for Diabetes and Hyperglycemia. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The objective of this project is to understand defects in insulin secretion that contribute to abnormal glucose metabolism in patients with diabetes. In particular the effects of signals released from the intestine to stimulate insulin secretion will be tested. Patients with type 2 diabetes will have insulin secretion in response to glucose and intestinal factors before and after insulin treatment to lower their blood glucose. It is expected that the results of this work will provide valuable information for treating diabetic people.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Hyperglycemia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 7, 2007
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2011
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 19.2 years ago

Interventions

insulin glarginedrug

Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.